Sleep Disorders, Circadian RhythmPhase 2NCT00593736
Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome
A Phase 2 study testing Ramelteon in people with Sleep Disorders, Circadian Rhythm, run by Takeda at 42 sites in United States.
Trial summary
The purpose of this study is to evaluate the ability of ramelteon, once daily (QD), to advance the timing of sleep in individuals with delayed sleep phase syndrome. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sleep Disorders, Circadian Rhythm
- What is being tested?
- Ramelteon
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 132 participants
- Where
- 42 sitesUnited States
- Study dates
- Oct 2007to May 2008
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Females of childbearing potential who is sexually active must agree to use adequate contraception from screening throughout the duration of the study.
- Must have a diagnosis of Delayed Sleep Phase Syndrome according to International Classification of Sleep Disorders criteria for at least 3 months.
- Based on sleep history, subject's habitual sleep time is more than 3 hours later than the desired sleep time.
- Must have had self reported insomnia which is defined per the sleep history as his or her sleep latency of at least 45 minutes when attempting to sleep at desired sleep time required by his or her work or school schedule.
- The subjective sleep latency via Post sleep questionnaire during outpatient screening period must be greater than or equal to 45 minutes during every working night or school night provided the subject went to bed at their desired sleep time.
- During single blind placebo run-in Polysomnography screening nights, subject is instructed to go to bed at their desired bed time and must demonstrate difficulty in falling asleep based on the following criteria:
Show all 16Show fewer
- During Polysomnography screening nights when the subject goes to bed at their desired sleep time or
- The average of total wake time
- Is in good health as determined by a medical and psychiatric history, physical examination, Electrocardiogram, and serum chemistry and hematology.
- Is able to complete self-rating scales via interactive voice response system, and has a touch tone phone.
- Is willing to comply with study procedures and restrictions with fixed sleep time and wake time during the study and to attend regularly scheduled clinic visits as specified in this protocol.
- Has a body mass index is between 18 and 34 kg/m2, inclusive.
- Has a negative urine test result for selected substances of abuse (including alcohol).
- Has a negative test result for hepatitis B surface antigen and hepatitis C virus antibody or history of human immunodeficiency virus.
- Has not used pharmacological sleep assistance for more than 4 times/week during the 3 months prior to Initial Screening.
- Must have discontinued use of all pharmacological sleep aids beginning 1 week prior to Visit 2 and for the duration of the trial.
Who cannot join
- Has a known hypersensitivity to ramelteon or related compounds, including melatonin and melatonin-related compounds or 5-hydroxytryptophan.
- Has participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives prior to the first dose of study medication, whichever is longer.
- Has flown across greater than 3 time zones within the past 3 months prior to administration of study medication.
- Has sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the administration of study medication.
- Has participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of study medication.
- Has a history of alcohol abuse within the past 12 months, as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, or regularly consumes more than 14 alcoholic drinks per week or consumes any alcoholic drinks within 24 hours of Screening Visit.
Show all 47Show fewer
- Has a history of drug abuse within the past 12 months.
- Has a current, clinically significant neurological (including cognitive), hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease, as determined by the investigator.
- Has a probable current diagnosis of another circadian rhythm disorder or a sleep disorder other than Delayed Sleep Phase Syndrome that is the primary cause of insomnia.
- Had an apnea hypopnea index greater than 10 on the first night of Polysomnography Screening.
- Has periodic limb movements during sleep with arousal index greater than 10 as seen on the first night of Polysomnography screening only.
- Has a positive urine drug screen or breathalyzer test.
- Has ever had a history of seizures; sleep apnea, restless leg syndrome, chronic obstructive pulmonary disease, fibromyalgia, or a positive test result for the aforementioned ailments on the screening Polysomnography, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
- Has a history of psychiatric disorder (including anxiety or depression) within the past 12 months.
- Smokes more than 3 cigarettes per day or uses tobacco products during nightly awakenings.
- Routinely consumes caffeine including coffee, tea and/or other caffeine-containing beverages or food averaging more than 600 mg of caffeine per day.
- Has used any central nervous system drug or other medications, including those used to treat psychiatric disorders, known to affect sleep/wake function within 1 week whichever is longer prior to the administration of single blind study drug.
- Used melatonin, or other drugs/supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug) whichever is longer prior to the first dose of single blind medication.
- Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Anxiolytics
- Hypnotics
- Antidepressants
- Anticonvulsants
- Sedating H1 antihistamines
- Systemic steroids
- Respiratory stimulants
- Decongestants
- Antipsychotics
- Muscle relaxants
- Over-the-counter and prescription diet aids
- Narcotic analgesics
- Beta Blockers
- St. John's wort
- Kava kava
- Ginkgo biloba
- Modafinil
- Coumadin
- Heparin
- Melatonin and all other drugs or supplements known to affect sleep/wake function will be prohibited within 1 week of the first dose of study medication and during the entire study.
- Has any clinically important abnormal finding as determined by a medical history, physical examination, Electrocardiogram, or clinical laboratory tests as determined by the investigator.
- Has a positive hepatitis panel including anti- Hepatitis A Virus, hepatitis B surface antigen or anti- hepatitis C virus.
- Has any additional condition(s) that in the investigator's opinion would:
- Affect sleep/wake function
- Prohibit the subject from completing the study, or
- Not be in the best interest of the subject.
- Exhibits a placebo response during single-blinded placebo run in period.
- Individuals with a habitual sleep time later than 4:00 am should not be included in the study.
Trial locations and contacts
42 sites in 1 country.
42 sites in 1 country
United States42 sites
Study site
Atlanta, Georgia
Study site
Austin, Texas
Study site
Birmingham, Alabama
Study site
Chevy Chase, Maryland
Study site
Chicago, Illinois
Study site
Cincinnati, Ohio
Study site
Clarks Summit, Pennsylvania
Study site
Colorado Springs, Colorado
Study site
Columbia, South Carolina
Study site
Crestview Hills, Kentucky
Study site
Danville, Indiana
Study site
Dublin, Ohio
Study site
Fountain Valley, California
Study site
Gainesville, Georgia
Study site
Glendale, California
Study site
Hallandale Bch, Florida
Study site
Hattiesburg, Mississippi
Study site
Hot Springs, Arkansas
Study site
Las Vegas, Nevada
Study site
Lincoln, Nebraska
Study site
Little Rock, Arkansas
Study site
Los Angeles, California
Study site
Macon, Georgia
Study site
Naples, Florida
Study site
New York, New York
Study site
Newton, Massachusetts
Study site
Overland Park, Kansas
Study site
Paducah, Kentucky
Study site
Pembroke Pines, Florida
Study site
Raleigh, North Carolina
Study site
Salem, Oregon
Study site
Salisbury, North Carolina
Study site
San Diego, California
Study site
Santa Monica, California
Study site
South Miami, Florida
Study site
Spring Hill, Florida
Study site
St. Petersburg, Florida
Study site
Toledo, Ohio
Study site
Topeka, Kansas
Study site
Tucson, Arizona
Study site
Tustin, California
Study site
Winter Park, Florida
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of Ramelteon to Advance the Timing of Sleep in Individuals With Delayed Sleep Phase Syndrome (DSPS)
The purpose of this study is to evaluate the ability of ramelteon, once daily (QD), to advance the timing of sleep in individuals with delayed sleep phase syndrome.
Read the detailed description
Delayed sleep phase syndrome is the most common circadian disorder in adolescents and most adults with the condition report onset of symptoms during childhood or adolescence. Delayed Sleep Phase Syndrome involves a chronic mismatch between the usual daily schedule required by the individual's environment and his or her circadian sleep wake pattern. Individuals suffering from delayed Sleep Phase Syndrome experience great difficulty when attempting to fall asleep before 1-2 am, if not later, as well as rising at acceptable hours of the morning despite having completely normal sleep architecture and sleep duration. Delayed Sleep Phase Syndrome is a sleep disorder that results from a dysregulation of the circadian sleep-wake rhythm. Delayed Sleep Phase Syndrome is often the cause of severe insomnia and is associated with excessive daytime sleepiness, major depressive disorder and severe disruption of education, work and social functioning. Its major symptom is extreme difficulty initiating sleep at a conventional hour and waking on time in the morning for school or work.
Ramelteon is a selective melatonin type 1 (MT1) and type 2 (MT2) receptor agonist. The purpose of this study is to evaluate the ability of ramelteon to advance the timing of sleep in individuals with delayed sleep phase syndrome. The effect of ramelteon will be analyzed based on collection of information from a post-sleep questionnaire completed by participants, and data collected by polysomnography in a sleep clinic setting. Total participation time involved in this study will be approximately 7 weeks.
- Conditions
- Sleep Disorders, Circadian Rhythm
- Being tested
- Ramelteon, Placebo
- Keywords
- Delayed sleep phase syndrome; drug therapy
- Medical subject headings
- Sleep Disorders, Circadian Rhythm
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RamelteonDrug
Also called Rozerem™, TAK-375
Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
RamelteonDrug
Also called Rozerem™, TAK-375
Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
RamelteonDrug
Also called Rozerem™, TAK-375
Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
PlaceboDrug
Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
| Study group | Role | What they receive |
|---|---|---|
| Ramelteon 1 mg QD | Experimental | Not described Receives: Drug: Ramelteon |
| Ramelteon 4 mg QD | Experimental | Not described Receives: Drug: Ramelteon |
| Ramelteon 8 mg QD | Experimental | Not described Receives: Drug: Ramelteon |
| Placebo QD | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7)
The elapsed time from the beginning of the polysomnography recording to the onset of the first 10 minutes of continuous sleep (ie, total number of epochs before the first 20 consecutive non-wake epochs divided by 2).
Measured: Nights 6-7
Secondary outcomes (59)
Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 13-14)
The elapsed time from the beginning of the polysomnography recording to the onset of the first 10 minutes of continuous sleep (ie, total number of epochs before the first 20 consecutive non-wake epochs divided by 2).
Measured: Nights 13-14
Total Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)
The sum of all of the minutes of Stages 1, 2, 3, 4, and rapid eye movement (REM) sleep.
Measured: Nights 6-7
Total Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)
The sum of all of the minutes of Stages 1, 2, 3, 4, and REM sleep.
Measured: Nights 13-14
Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-3 Hours) (Nights 6-7)
The total sleep time divided by time-in-bed, multiplied by 100.
Measured: Nights 6-7
Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-3 Hours) (Nights 13-14)
The total sleep time divided by time-in-bed, multiplied by 100.
Measured: Nights 13-14
Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-8 Hours) (Nights 6-7)
The total sleep time divided by time-in-bed, multiplied by 100.
Measured: Nights 6-7
Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-8 Hours) (Nights 13-14)
The total sleep time divided by time-in-bed, multiplied by 100.
Measured: Nights 13-14
Wake Time After Sleep Onset Over a 2-night Average Measured by Polysomnography (Nights 6-7)
The number of wake minutes after the onset of persistent sleep prior to the end of recording.
Measured: Nights 6-7
Wake Time After Sleep Onset Over a 2-night Average Measured by Polysomnography (Nights 13-14)
The number of wake minutes after the onset of persistent sleep prior to the end of recording.
Measured: Nights 13-14
Number of Awakenings Over a 2-night Average Measured by Polysomnography (Nights 6-7)
The number of times after onset of persistent sleep that there is a wake entry of at least 2 epochs in duration. Each entry must be separated by stage 2, stage 3/4 non-REM (NREM) sleep, or REM sleep to be counted.
Measured: Nights 6-7
Number of Awakenings Over a 2-night Average Measured by Polysomnography (Nights 13-14)
The number of times after onset of persistent sleep that there is a wake entry of at least 2 epochs in duration. Each entry must be separated by stage 2, stage 3/4 non-REM (NREM) sleep, or REM sleep to be counted.
Measured: Nights 13-14
Total Wake Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)
The sum of all the minutes of Stage Wake from the beginning of the recording to the end of recording.
Measured: Nights 6-7
Total Wake Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)
The sum of all the minutes of Stage Wake from the beginning of the recording to the end of recording.
Measured: Nights 13-14
Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Sleep time was measured as the clock time the subject went to sleep. Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 6-7
Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Sleep time was measured as the clock time the subject went to sleep. Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 13-14
Wake Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Wake Time was measured as the clock time that the subject got up in the morning. Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 6-7
Wake Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Wake Time was measured as the clock time that the subject got up in the morning. Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 13-14
Total Sleep Time Measured by Actigraphy (Nights 6-7)
Total sleep time calculated using the total number of epochs (number of movements recorded by actigraphy watch worn by subject) that are less than or equal to 40, measured between the start time and end time during the nocturnal sleep interval, scored as SLEEP by the actigraphy software.
Measured: Nights 6-7
Total Sleep Time Measured by Actigraphy (Nights 13-14)
Total sleep time pertains to the total number of epochs (number of movements recorded by actigraphy watch worn by subject) that are less than or equal to 40, measured between the start time and end time during the nocturnal sleep interval, scored as SLEEP by the actigraphy software.
Measured: Nights 13-14
Sleep Efficiency Measured by Actigraphy (Nights 6-7)
Sleep efficiency pertains to the scored total sleep time (recorded by actigraphy watch worn by subject) of the sleep interval divided by total time in bed minus total invalid time (Sleep/Wake), multiplied by 100.
Measured: Nights 6-7
Sleep Efficiency Measured by Actigraphy (Nights 13-14)
Sleep efficiency pertains to the scored total sleep time (recorded by actigraphy watch worn by subject) of the sleep interval divided by total time in bed minus total invalid time (Sleep/Wake), multiplied by 100.
Measured: Nights 13-14
Wake Time During Sleep Interval Measured by Actigraphy (Nights 6-7)
Wake time during sleep is the total number of epochs (number of movements recorded by actigraphy watch worn by subject) between the start time and the end time of the given sleep interval, scored as WAKE by the software (or manually set as WAKE by the practitioner using the software), multiplied by the Epoch length in minutes.
Measured: Nights 6-7
Wake Time During Sleep Interval Measured by Actigraphy (Nights 13-14)
Wake time during sleep is the total number of epochs (number of movements recorded by actigraphy watch worn by subject) between the start time and the end time of the given sleep interval, scored as WAKE by the software (or manually set as WAKE by the practitioner using the software), multiplied by the Epoch length in minutes.
Measured: Nights 13-14
Wake Bouts Measured by Actigraphy (Nights 6-7)
The number of wake bouts pertains to the total number of continuous blocks (recorded by actigraphy watch worn by subject), with one or more epochs in duration, and with each epoch of each clock scored as WAKE between the start time and the end time of the given interval.
Measured: Nights 6-7
Wake Bouts Measured by Actigraphy (Nights 13-14)
The number of wake bouts pertains to the total number of continuous blocks (recorded by actigraphy watch worn by subject), with one or more epochs in duration, and with each epoch of each clock scored as WAKE between the start time and the end time of the given interval.
Measured: Nights 13-14
Sleep Latency Measured by Actigraphy (Nights 6-7)
The elapsed time from the beginning of the recording to the onset of the first 10 minutes of continuous sleep (recorded by actigraphy watch worn by subject).
Measured: Nights 6-7
Sleep Latency Measured by Actigraphy (Nights 13-14)
The elapsed time from the beginning of the recording to the onset of the first 10 minutes of continuous sleep (recorded by actigraphy watch worn by subject).
Measured: Nights 13-14
Sleep Time Measured by Actigraphy (Nights 6-7)
Clock time subject goes to sleep (recorded by actigraphy watch worn by subject). Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 6-7
Sleep Time Measured by Actigraphy (Nights 13-14)
Clock time subject goes to sleep (recorded by actigraphy watch worn by subject). Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 13-14
Wake Time Measured by Actigraphy (Nights 6-7)
Clock time subject wakes up (recorded by actigraphy watch worn by subject). Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 6-7
Wake Time Measured by Actigraphy (Nights 13-14)
Clock time subject wakes up (recorded by actigraphy watch worn by subject). Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 13-14
Subjective Sleep Latency Measured by a Post-sleep Questionnaire (Nights 6-7)
Subjective sleep latency was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How long do you think it took you to fall asleep last night?"
Measured: Nights 6-7
Subjective Sleep Latency Measured by a Post-sleep Questionnaire (Nights 13-14)
Subjective sleep latency was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How long do you think it took you to fall asleep last night?"
Measured: Nights 13-14
Subjective Total Sleep Time Measured by a Post-sleep Questionnaire (Nights 6-7)
Subjective total sleep time was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How long (total hours and minutes) do you think you slept last night?"
Measured: Nights 6-7
Subjective Total Sleep Time Measured by a Post-sleep Questionnaire (Nights 13-14)
Subjective total sleep time was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How long (total hours and minutes) do you think you slept last night?"
Measured: Nights 13-14
Subjective Wake Time After Sleep Onset Measured by a Post-sleep Questionnaire (Nights 6-7)
Subjective wake time after sleep onset was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "Did you wake up during the night? If "yes", what is the total time you think you were awake?"
Measured: Nights 6-7
Subjective Wake Time After Sleep Onset Measured by a Post-sleep Questionnaire (Nights 13-14)
Subjective wake time after sleep onset was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "Did you wake up during the night? If "yes", what is the total time you think you were awake?"
Measured: Nights 13-14
Subjective Number of Awakenings Measured by a Post-sleep Questionnaire (Nights 6-7)
Subjective number of awakenings was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "Did you wake up during the night? If "yes", how many times do you think you woke up?"
Measured: Nights 6-7
Subjective Number of Awakenings Measured by a Post-sleep Questionnaire (Nights 13-14)
Subjective number of awakenings was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "Did you wake up during the night? If "yes", how many times do you think you woke up?"
Measured: Nights 13-14
Subjective Sleep Quality Measured by a Post-sleep Questionnaire (Nights 6-7)
Subjective sleep quality was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe the quality of your sleep last night?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.
Measured: Nights 6-7
Subjective Sleep Quality Measured by a Post-sleep Questionnaire (Nights 13-14)
Subjective sleep quality was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe the quality of your sleep last night?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.
Measured: Nights 13-14
Subjective Sleep Time Measured by a Post-sleep Questionnaire (Nights 6-7)
Subjective sleep time was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "What time did you try to go to sleep last night?" Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 6-7
Subjective Sleep Time Measured by a Post-sleep Questionnaire (Nights 13-14)
Subjective sleep time was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "What time did you try to go to sleep last night?" Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Nights 13-14
Subjective Getting up in the Morning Measured by a Post-sleep Questionnaire (Nights 6-7)
The score was an average of 2 nights responses. If subjects had a work or school day, the answer to, "How easy was it for you to wake or get up in the morning when on a school or working night?" was based on the following scale: Extremely Difficult =7; Very Difficult =6; Difficult =5; Neither =4; Easy =3; Very Easy =2; Extremely Easy =1.
Measured: Nights 6-7
Subjective Getting up in the Morning Measured by a Post-sleep Questionnaire (Nights 13-14)
The score was an average of 2 nights responses. If subjects had a work or school day, the answer to, "How easy was it for you to wake or get up in the morning when on a school or working night?" was based on the following scale: Extremely Difficult =7; Very Difficult =6; Difficult =5; Neither =4; Easy =3; Very Easy =2; Extremely Easy =1.
Measured: Nights 13-14
Subjective Ability to Concentrate in the Morning Measured by a Post-sleep Questionnaire (Nights 6-7)
Subjective ability to concentrate was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe your ability to concentrate this morning?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.
Measured: Nights 6-7
Subjective Ability to Concentrate in the Morning Measured by a Post-sleep Questionnaire (Nights 13-14)
Subjective ability to concentrate was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe your ability to concentrate this morning?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.
Measured: Nights 13-14
Subjective Level of Alertness Measured by a Post-sleep Questionnaire (Nights 6-7)
Subjective level of alertness was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe your level of alertness this morning?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.
Measured: Nights 6-7
Subjective Level of Alertness Measured by a Post-sleep Questionnaire (Nights 13-14)
Subjective level of alertness was an average of 2 nights responses and measured by post-sleep questionnaire in response to the question, "How would you describe your level of alertness this morning?" Scores were based on the following scale: Extremely Poor=7; Very Poor=6; Poor=5; Fair=4; Good=3; Very Good=2; Excellent=1.
Measured: Nights 13-14
Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Digit Symbol Substitution Test
The number of correct digit-for-number substitutions on a Digit Symbol Substitution Test in the 90-second period was recorded to assess psychomotor and cognitive function. The score was the average of 2 mornings' tests. Worst Value: 0. Best Value: No Limit.
Measured: Day 15
Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Memory Recall Test--Immediate
After 16 words were read to a subject, a subject was given 2 minutes to write down as many words as he/she remembered. The correct number of words written was scored, and the average of 2 mornings' tests was calculated.
Measured: Day 15
Next Morning Residual Effects Assessments of Psychomotor and Cognitive Function Via Memory Recall Test--Delayed
After 16 words were read to a subject, a subject waited 1 minute and then was given 2 minutes to write down as many words as he/she remembered. The correct number of words written was scored, and the average of 2 mornings' tests was calculated.
Measured: Day 15
Visual Analogue Scale for Mood
Subjects marked visual scales (in millimeters) that represented ranges of emotions (eg, calm to anxious; normal to bloated; energetic to fatigued). Individual subject composite scores were calculated, and the average of 2 tests were analyzed. Worst Value: 0 mm. Best Value: 100 mm. The farther to the left a subject marks, the better their mood; farther to the right, the more distressed the mood. Higher numbers indicate a more distressed mood.
Measured: Day 15
Visual Analogue Scale for Feelings
Subjects marked visual scales (in millimeters) that represented ranges of emotions (eg, calm to anxious; normal to bloated; energetic to fatigued). Individual subject composite scores were calculated, and the average of 2 tests were analyzed. Worst Value:0 mm.. Best Value:100 mm.. The farther to the left a subject marks, the better their mood; farther to the right, the more distressed the mood. Higher numbers indicate a more distressed mood.
Measured: Day 15
The Time of Dim Light Melatonin Secretion Onset
Linear Dim Light Melatonin Secretion Onset is defined as the first time of the evening (on a 24-hour clock) when the melatonin level rises above 3.0 pg/ml with a positive slope. Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Day 15
The Time of Dim Light Melatonin Secretion Offset
Dim Light Melatonin Secretion Offset is defined as the first time of the morning (on a 24-hour clock) when the melatonin drops to below 3 pg/mL with a negative slope. Units are hours and minutes on a 24-hour clock, expressed in decimal time.
Measured: Day 15
The Total Duration of Secretion of Melatonin
The total duration of time from Dim Light Melatonin Secretion Onset to Dim Light Melatonin Secretion Offset.
Measured: Day 15
The Area Under the Concentration-time Curve of Melatonin From 0 to 24 Hours
Area under the concentration-time curve is a measure of total drug exposure.
Measured: Day 15
Average Cmax (Maximum Observed Plasma Concentration) Calculated as the Average of Three Highest Cmax Observations Within the Sampling Period.
Average Cmax calculated as the average of three highest Cmax observations within the sampling period.
Measured: Day 15
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2008 (estimated)
- Study startOct 2007
- Primary completionMay 2008
- Study completionMay 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Sleep Disorders, Circadian RhythmStudies of the same condition, open and under way.
- More trials run by TakedaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 132 participants (actual)
Sponsor and investigators
- Lead sponsor
- Takeda
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director Clinical Science, Study director, Takeda
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00593736
- Sponsor's protocol ID
- 01-04-TL-375-044
- Status last verified
- Feb 2012
- First submitted
- 2 Jan 2008
- Last updated
- 28 Feb 2012
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Feb 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of Ramelteon to Advance the Timing of Sleep in Individuals With Delayed Sleep Phase Syndrome (DSPS)
- ClinicalTrials.gov ID
- NCT00593736
- Acronym / sponsor ID
- 01-04-TL-375-044
- Conditions
- Sleep Disorders, Circadian Rhythm
- Keywords
- Delayed sleep phase syndrome; drug therapy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 132 participants (actual)
- Lead sponsor
- TakedaIndustry (pharma, biotech, devices)
- Study start
- Oct 2007
- Primary completion
- May 2008 (actual)
- Study completion
- May 2008 (actual)
- First posted
- 15 Jan 2008 (estimated)
- Results
- Posted 9 Mar 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the ability of ramelteon, once daily (QD), to advance the timing of sleep in individuals with delayed sleep phase syndrome.
Detailed description
Delayed sleep phase syndrome is the most common circadian disorder in adolescents and most adults with the condition report onset of symptoms during childhood or adolescence. Delayed Sleep Phase Syndrome involves a chronic mismatch between the usual daily schedule required by the individual's environment and his or her circadian sleep wake pattern. Individuals suffering from delayed Sleep Phase Syndrome experience great difficulty when attempting to fall asleep before 1-2 am, if not later, as well as rising at acceptable hours of the morning despite having completely normal sleep architecture and sleep duration. Delayed Sleep Phase Syndrome is a sleep disorder that results from a dysregulation of the circadian sleep-wake rhythm. Delayed Sleep Phase Syndrome is often the cause of severe insomnia and is associated with excessive daytime sleepiness, major depressive disorder and severe disruption of education, work and social functioning. Its major symptom is extreme difficulty initiating sleep at a conventional hour and waking on time in the morning for school or work.
Ramelteon is a selective melatonin type 1 (MT1) and type 2 (MT2) receptor agonist. The purpose of this study is to evaluate the ability of ramelteon to advance the timing of sleep in individuals with delayed sleep phase syndrome. The effect of ramelteon will be analyzed based on collection of information from a post-sleep questionnaire completed by participants, and data collected by polysomnography in a sleep clinic setting. Total participation time involved in this study will be approximately 7 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Ramelteon 1 mg QD | Experimental | Drug: Ramelteon |
| Ramelteon 4 mg QD | Experimental | Drug: Ramelteon |
| Ramelteon 8 mg QD | Experimental | Drug: Ramelteon |
| Placebo QD | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Females of childbearing potential who is sexually active must agree to use adequate contraception from screening throughout the duration of the study.
- Must have a diagnosis of Delayed Sleep Phase Syndrome according to International Classification of Sleep Disorders criteria for at least 3 months.
- Based on sleep history, subject's habitual sleep time is more than 3 hours later than the desired sleep time.
- Must have had self reported insomnia which is defined per the sleep history as his or her sleep latency of at least 45 minutes when attempting to sleep at desired sleep time required by his or her work or school schedule.
- The subjective sleep latency via Post sleep questionnaire during outpatient screening period must be greater than or equal to 45 minutes during every working night or school night provided the subject went to bed at their desired sleep time.
Key exclusion criteria (47 listed)
- Has a known hypersensitivity to ramelteon or related compounds, including melatonin and melatonin-related compounds or 5-hydroxytryptophan.
- Has participated in any other investigational study and/or taken any investigational drug within 30 days or 5 half-lives prior to the first dose of study medication, whichever is longer.
- Has flown across greater than 3 time zones within the past 3 months prior to administration of study medication.
- Has sleep schedule changes required by employment (eg, shift worker) within 3 months prior to the administration of study medication.
- Has participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of study medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RamelteonAlso: Rozerem™, TAK-375Ramelteon 1 mg, tablets, orally, once daily for up to two weeks. | Drug | Ramelteon 1 mg QD |
| RamelteonAlso: Rozerem™, TAK-375Ramelteon 4 mg, tablets, orally, once daily for up to two weeks. | Drug | Ramelteon 4 mg QD |
| RamelteonAlso: Rozerem™, TAK-375Ramelteon 8 mg, tablets, orally, once daily for up to two weeks. | Drug | Ramelteon 8 mg QD |
| PlaceboRamelteon placebo-matching tablets, orally, once daily for up to two weeks. | Drug | Placebo QD |
Primary outcome
Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Time frame: Nights 6-7
The elapsed time from the beginning of the polysomnography recording to the onset of the first 10 minutes of continuous sleep (ie, total number of epochs before the first 20 consecutive non-wake epochs divided by 2).
59 secondary outcomes
Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Time frame: Nights 13-14
Total Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Time frame: Nights 6-7
Total Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Time frame: Nights 13-14
Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-3 Hours) (Nights 6-7)
Time frame: Nights 6-7
Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-3 Hours) (Nights 13-14)
Time frame: Nights 13-14
Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-8 Hours) (Nights 6-7)
Time frame: Nights 6-7
Sleep Efficiency Over a 2-night Average Measured by Polysomnography (0-8 Hours) (Nights 13-14)
Time frame: Nights 13-14
Wake Time After Sleep Onset Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Time frame: Nights 6-7
Wake Time After Sleep Onset Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Time frame: Nights 13-14
Number of Awakenings Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Time frame: Nights 6-7
Number of Awakenings Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Time frame: Nights 13-14
Total Wake Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Time frame: Nights 6-7
Total Wake Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Time frame: Nights 13-14
Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Time frame: Nights 6-7
Sleep Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Time frame: Nights 13-14
Wake Time Over a 2-night Average Measured by Polysomnography (Nights 6-7)
Time frame: Nights 6-7
Wake Time Over a 2-night Average Measured by Polysomnography (Nights 13-14)
Time frame: Nights 13-14
Total Sleep Time Measured by Actigraphy (Nights 6-7)
Time frame: Nights 6-7
Total Sleep Time Measured by Actigraphy (Nights 13-14)
Time frame: Nights 13-14
Sleep Efficiency Measured by Actigraphy (Nights 6-7)
Time frame: Nights 6-7
Sleep Efficiency Measured by Actigraphy (Nights 13-14)
Time frame: Nights 13-14
Wake Time During Sleep Interval Measured by Actigraphy (Nights 6-7)
Time frame: Nights 6-7
Wake Time During Sleep Interval Measured by Actigraphy (Nights 13-14)
Time frame: Nights 13-14
Wake Bouts Measured by Actigraphy (Nights 6-7)
Time frame: Nights 6-7
Wake Bouts Measured by Actigraphy (Nights 13-14)
Time frame: Nights 13-14
Sleep Latency Measured by Actigraphy (Nights 6-7)
Time frame: Nights 6-7
Sleep Latency Measured by Actigraphy (Nights 13-14)
Time frame: Nights 13-14
Sleep Time Measured by Actigraphy (Nights 6-7)
Time frame: Nights 6-7
Sleep Time Measured by Actigraphy (Nights 13-14)
Time frame: Nights 13-14
Wake Time Measured by Actigraphy (Nights 6-7)
Time frame: Nights 6-7
Wake Time Measured by Actigraphy (Nights 13-14)
Time frame: Nights 13-14
Subjective Sleep Latency Measured by a Post-sleep Questionnaire (Nights 6-7)
Time frame: Nights 6-7
Subjective Sleep Latency Measured by a Post-sleep Questionnaire (Nights 13-14)
Time frame: Nights 13-14
Subjective Total Sleep Time Measured by a Post-sleep Questionnaire (Nights 6-7)
Time frame: Nights 6-7
Subjective Total Sleep Time Measured by a Post-sleep Questionnaire (Nights 13-14)
Time frame: Nights 13-14
Subjective Wake Time After Sleep Onset Measured by a Post-sleep Questionnaire (Nights 6-7)
Time frame: Nights 6-7
Subjective Wake Time After Sleep Onset Measured by a Post-sleep Questionnaire (Nights 13-14)
Time frame: Nights 13-14
Subjective Number of Awakenings Measured by a Post-sleep Questionnaire (Nights 6-7)
Time frame: Nights 6-7
Subjective Number of Awakenings Measured by a Post-sleep Questionnaire (Nights 13-14)
Time frame: Nights 13-14
Subjective Sleep Quality Measured by a Post-sleep Questionnaire (Nights 6-7)
Time frame: Nights 6-7
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Feb 2012.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Rozerem Package InsertLink provided by the sponsor.
Related trials for Sleep Disorders, Circadian Rhythm
Enrolling by invitation
Sleep and Activity For Eating Disorders
Eating Disorders, Anorexia Nervosa
RecruitingObservational study
Body Clocks - Coordination of Peripheral and Central Oscillators
Circadian Dysregulation
Active, not recruiting
Countermeasures to Circadian Misalignment
Circadian Rhythm Sleep Disorder of Shift Work Type, Metabolic Disease
Enrolling by invitationObservational study
Digital Phenotypes for Predicting Depression_Validation
Major Depressive Disorder, Bipolar I Disorder
Not yet recruitingObservational study
Circadian Clock Proteins in Gingival Crevicular Fluid of Individuals With and Without Circadian Rhythm Disruption
Gingivitis, Circadian Rhythm Disruption
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director Clinical Science study director
Takeda
42 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Ramelteon in people with Sleep Disorders, Circadian Rhythm, run by Takeda at 42 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 47 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Feb 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 42 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Mar 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7) (time frame: Nights 6-7). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2012.